Evidence map›Paper›PMID 41089309›Full record

ReviewJournal of physics D: Applied physics2025

Emerging strategies in radiation therapy: promises and challenges of spatial fractionation, ultra-high dose rates, and nanoparticles.

Hamid Ghaznavi, Mohammad Rezaee, Francisco Reynoso, Arash Darafsheh

Abstract readReview
In one paragraph

Review in Journal of physics D: Applied physics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. A review on radiochromic film dosimetry in radiation therapy.Journal of applied clinical medical physics · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hamid GhaznaviDepartment of Radiation Oncology, WashU Medicine, St. Louis, MO 63110, United States of America.ORCID https://orcid.org/0000-0002-7118-8309
Mohammad RezaeeDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, MD 21231, United States of America.ORCID https://orcid.org/0000-0003-4607-9570
Francisco ReynosoVarian Medical Systems, Palo Alto, CA 94304, United States of America.ORCID https://orcid.org/0000-0001-5183-2841
Arash DarafshehDepartment of Radiation Oncology, WashU Medicine, St. Louis, MO 63110, United States of America.ORCID https://orcid.org/0000-0003-4148-0891

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiation therapy (RT) employs ionizing radiation to kill cancerous cells. However, delivering radiation to tumors, typically embedded within normal tissues, inevitably exposes healthy organs to radiation, leading to collateral damage. This creates a tradeoff between the tumor control probability and normal tissue complication probability, ultimately limiting the dose that can be safely administered. While highly conformal RT techniques have improved tumor targeting and treatment efficacy, they remain inadequate for treating large and radioresistant tumors, pointing out the need for alternative strategies. Spatially fractionated RT, ultra-high dose rate RT, and nanoparticle-enhanced RT are emerging techniques with promise in enhancing tumor control while minimizing normal tissue toxicity. Successful clinical translation of these advanced techniques requires cross-disciplinary efforts aimed at technological innovation, a deeper understanding of the underlying radiobiological mechanisms, and the development of early-phase clinical trials. This paper provides an overview of these techniques and their associated challenges and opportunities.

Indexed as

dosimetryFLASHnanoparticleradiation therapyspatially fractionated radiation therapyultra-high dose rate

Identifiers

PMID41089309
PMCPMC12516303

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.